ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Health Technology

Biotechnology

Health

Pharmaceutical

Other Science

Science

Oncology

ITM

More Like This

Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

PR Newswire associated0

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors

PR Newswire associated0

Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

PR Newswire associated0

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

PR Newswire associated0

Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS

PR Newswire associated0

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors

PR Newswire associated0

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer